Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
16.46
-0.49 (-2.89%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Tango Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Revenue | 62.38 | 42.07 | 36.53 | 24.86 | 37.04 | Upgrade
|
| Revenue Growth (YoY) | 48.29% | 15.17% | 46.93% | -32.89% | 383.83% | Upgrade
|
| Cost of Revenue | 132.17 | 143.92 | 115.2 | 105.91 | 77.64 | Upgrade
|
| Gross Profit | -69.78 | -101.85 | -78.67 | -81.05 | -40.59 | Upgrade
|
| Selling, General & Admin | 41.51 | 43.75 | 35.5 | 30.03 | 17.6 | Upgrade
|
| Operating Expenses | 41.51 | 43.75 | 35.5 | 30.03 | 17.6 | Upgrade
|
| Operating Income | -111.29 | -145.6 | -114.17 | -111.07 | -58.19 | Upgrade
|
| Interest & Investment Income | 5.63 | 7.89 | 6.62 | 1.46 | 0.5 | Upgrade
|
| Other Non Operating Income (Expenses) | 4.07 | 7.61 | 5.94 | 1.49 | -0.25 | Upgrade
|
| Pretax Income | -101.59 | -130.09 | -101.61 | -108.12 | -57.94 | Upgrade
|
| Income Tax Expense | 0 | 0.21 | 0.13 | 0.05 | 0.29 | Upgrade
|
| Net Income | -101.59 | -130.3 | -101.74 | -108.18 | -58.24 | Upgrade
|
| Net Income to Common | -101.59 | -130.3 | -101.74 | -108.18 | -58.24 | Upgrade
|
| Shares Outstanding (Basic) | 116 | 109 | 95 | 88 | 62 | Upgrade
|
| Shares Outstanding (Diluted) | 116 | 109 | 95 | 88 | 62 | Upgrade
|
| Shares Change (YoY) | 6.35% | 15.50% | 7.69% | 41.40% | 94.50% | Upgrade
|
| EPS (Basic) | -0.87 | -1.19 | -1.08 | -1.23 | -0.94 | Upgrade
|
| EPS (Diluted) | -0.87 | -1.19 | -1.08 | -1.23 | -0.94 | Upgrade
|
| Free Cash Flow | -139.93 | -132.26 | -119.51 | -116.77 | -61.36 | Upgrade
|
| Free Cash Flow Per Share | -1.21 | -1.21 | -1.26 | -1.33 | -0.99 | Upgrade
|
| Gross Margin | -111.86% | -242.10% | -215.38% | - | -109.59% | Upgrade
|
| Operating Margin | -178.39% | -346.09% | -312.57% | -446.79% | -157.09% | Upgrade
|
| Profit Margin | -162.85% | -309.73% | -278.55% | -435.14% | -157.21% | Upgrade
|
| Free Cash Flow Margin | -224.31% | -314.38% | -327.18% | -469.72% | -165.66% | Upgrade
|
| EBITDA | -109.01 | -143.1 | -111.76 | -109.46 | -57.29 | Upgrade
|
| EBITDA Margin | -174.74% | - | - | - | -154.67% | Upgrade
|
| D&A For EBITDA | 2.28 | 2.5 | 2.42 | 1.61 | 0.9 | Upgrade
|
| EBIT | -111.29 | -145.6 | -114.17 | -111.07 | -58.19 | Upgrade
|
| EBIT Margin | -178.39% | - | - | - | -157.09% | Upgrade
|
| Revenue as Reported | 62.38 | 42.07 | 36.53 | 24.86 | 37.04 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.